Is the JAK2V617F mutation detectable in healthy volunteers?
β Scribed by Christophe Martinaud; Patrick Brisou; Marie-Joelle Mozziconacci
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 705 KB
- Volume
- 85
- Category
- Article
- ISSN
- 0361-8609
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract The discovery this year of a single mutation in the Janus Kinase (__JAK__)β2 gene in a high percentage of cases of polycythaemia vera (PV), essential thrombocythaemia (ET) and myelofibrosis suggests that it maybe the underlying molecular mechanism for these disorders. Different approach
reductase enzyme mutation, 5Gdel1G of gen PAI-1) and hyperhomocysteinaemia up to 24 mcmol/L were also discovered. Patient received interferon-alpha, hydroxyurea, acetylsalicylic acid, sulodexide, vitamin therapy B6, B12 with positive effect. We observed disappearance of ascites, reduction of the siz
JAK2V617F is a common mutation in chronic myeloproliferative diseases (CMPDs). We have developed a system utilizing JAK2V617Fspecific guanine quenching probe (QP-system) to detect JAK2V617F. With QP-system, results can be obtained from 100 l of blood within 90 min. We compared QP-system with direct